AIDS passive immunotherapy animal experiment was successful: a shot, half a year
Release date: 2016-04-28
A research team in the United States reported that they developed a therapy that would allow monkeys to be protected from the apes version of HIV (SHIV) for almost six months with a single injection. This study is of great significance in preventing the spread of AIDS in high-risk groups.
The passive immunization method of hepatitis A can provide several months of protection before an effective vaccine is obtained. Previous studies have found that animals that acquire HIV-1 virus antibodies within 1 to 2 days before exposure to high-dose viruses can also show their ability to block viral infections. However, the long-term effectiveness of this passive immunotherapy has not been experimentally confirmed.
In a new study, the Malcolm of the National Institute of Allergy and Infectious Diseases. A. Martin and his colleagues hope to solve this problem to confirm whether passive immunotherapy like hepatitis A can continue to work against HIV infection.
Researchers published a paper on Nature's website saying they simulated the way humans were infected with HIV in the control group's nine macaques, and the average time to detect infection was three weeks. They then injected one dose of three different antibodies into each of three groups of six animals and exposed them to the virus for one week. It was found that the time of infection of all the antibody-receiving groups was delayed, and the longest protection period lasted for 23 weeks. The duration of protection was directly related to antibody strength and half-life. They also found that the half-life of the least potent antibody can be extended by introducing variants into the amino acid.
The researchers said that such antibodies could improve their overall ability to block the spread of drug-resistant HIV-1 strains, providing a proof of concept for the prevention and treatment of HIV-1. However, more research is needed to confirm the effectiveness of this therapy on the human body and whether it can replace the HIV-1 vaccine.
Source: China Science and Technology Network - Technology Daily
Shanghai J.Shine Co.,Ltd , https://www.jshinechem.com